PTPiyanit Tharmaphornpilas

Piyanit Tharmaphornpilas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Piyanit Tharmaphornpilas has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Effectiveness of COVID-19 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-Negative Nationwide Case–Control Study

    by Natthaprang Nittayasoot, Rapeepong Suphanchaimat, Panithee Thammawijaya, Chuleeporn Jiraphongsa, Taweesap Siraprapasiri, Kritchavat Ploddi, Chakkarat Pittayawonganon, Surakameth Mahasirimongkol, Piyanit Tharmaphornpilas

    Due to the widespread Omicron variant of SARS-CoV-2 in Thailand, the effectiveness of COVID-19 vaccines has become a major issue. The primary objective of this study is to examine the real-world effectiveness of COVID-19 vaccines based on secondary data acquired under normal circumstances in a real-world setting, to protect against treatment with invasive ventilation of pneumonia during January to April 2022, a period when Omicron was predominant. We conducted a nationwide test-negative case–control study. The case and control were matched with a ratio of 1:4 in terms of age, date of specimen collection, and hospital collection specimen and the odds ratio was calculated using conditional logistic regression. Overall, there was neither a distinction between mix-and-match regimens and homologous mRNA regimens against severe symptoms, nor was there a decline of the protective effect over the study period. The third and fourth dose boosters with ChAdOx1 nCoV-19 or mRNA vaccines provided high levels of protection against severe outcomes, approximately 87% to 100%, whereas two doses provided a moderate degree (70%). Thus, this study concludes that current national vaccine strategies provide favourable protective benefits against the Omicron variant. All Thais should receive at least two doses, while high-risk or vulnerable groups should be administered at least three doses.


  • Open Access

    Real-World Effectiveness of Mix-and-Match Vaccine Regimens against SARS-CoV-2 Delta Variant in Thailand: A Nationwide Test-Negative Matched Case-Control Study

    by Rapeepong Suphanchaimat, Natthaprang Nittayasoot, Chuleeporn Jiraphongsa, Panithee Thammawijaya, Punsapach Bumrungwong, Atthavit Tulyathan, Nontawit Cheewaruangroj, Chakkarat Pittayawonganon, Piyanit Tharmaphornpilas

    The objective of this study is to explore the real-world effectiveness of various vaccine regimens to tackle the epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant in Thailand during September–December 2021. We applied a test-negative case control study, using nationwide records of people tested for SARS-CoV-2. Each case was matched with two controls with respect to age, detection date, and specimen collection site. A conditional logistic regression was performed. Results were presented in the form vaccine effectiveness (VE) and 95% confidence interval. A total of 1,460,458 observations were analyzed. Overall, the two-dose heterologous prime-boost, ChAdOx1 + BNT162b2 and CoronaVac + BNT162b2, manifested the largest protection level (79.9% (74.0–84.5%) and 74.7% (62.8–82.8%)) and remained stable over the whole study course. The three-dose schedules (CoronaVac + CoronaVac + ChAdOx1, and CoronaVac + CoronaVac + BNT162b2) expressed very high degree of VE estimate (above 80.0% at any time interval). Concerning severe infection, almost all regimens displayed very high VE estimate. For the two-dose schedules, heterologous prime-boost regimens seemed to have slightly better protection for severe infection relative to homologous regimens. Campaigns to expedite the rollout of third-dose booster shot should be carried out. Heterologous prime-boost regimens should be considered as an option to enhance protection for the entire population.


  • Open Access

    Rapid method through routine data to evaluate real-world vaccine effectiveness against coronavirus disease 2019 (COVID-19) infection: lessons from Thailand

    by Natthaprang Nittayasoot, Panithee Thammawijaya, Piyanit Tharmaphornpilas, Chalo Sansilapin, Chuleeporn Jiraphongsa, Rapeepong Suphanchaimat

    The objective of this article is to draw lessons from the Thai experience in estimating vaccine effectiveness (VE) for coronavirus disease 2019 (COVID-19) based on routine service data. We found that a matched case–control design, using probability-based controls representing the varying vaccine coverage across the population over time, yielded a valid result for VE assessment. The proposed design has an advantage in its applicability drawing from the routine data monitoring system. Future studies that exercise other designs, such as test-negative and cohort studies, are recommended in order to compare and contrast the findings across different designs. To implement a continuous monitoring system on VE, the integration of data from different sources is needed. This requires long-term investment in the data monitoring system for the entire healthcare system.


  • Evaluating the first introduction of rotavirus vaccine in Thailand: Moving from evidence to policy

    by Piyanit Tharmaphornpilas, Suchada Jiamsiri, Somchit Boonchaiya, Onwipa Rochanathimoke, Wiravan Thinyounyong, Sumana Tuntiwitayapun, Ratigorn Guntapong, Arthorn Riewpaiboon, Aim-On Rasdjarmrearnsook, Roger I. Glass


  • Open Access

    Seroprevalence of Antibodies to Measles, Mumps, and Rubella among Thai Population: Evaluation of Measles/MMR Immunization Programme

    by Piyanit Tharmaphornpilas, Pornsak Yoocharean, Aim-Orn Rasdjarmrearnsook, Apiradee Theamboonlers, Yong Poovorawan

    Stored serum specimens, from four regions of Thailand, of healthy children attending well baby clinics and of healthy people with acute illnesses visiting outpatient clinics were randomly sampled and tested for IgG antibody to measles, mumps, and rubella (MMR). The immunity patterns of rubella and mumps fitted well with the history of rubella and MMR vaccination, seroprotective rates being over 85% among those aged over seven years. A high proportion of younger children acquired the infection before the age of vaccination. MMR vaccination should preferably be given to children at an earlier age. For measles, 73% seroprotective rates among children, aged 8-14 years, who should have received two doses of measles/MMR vaccine, were lower than expected. This finding was consistent with the age-group reported in outbreaks of measles in Thailand. The apparent ineffectiveness (in relation to measles) of MMR immunization of 1st grade students warrants further studies. Key words: Antibodies; Immunization; Measles; Measles vaccine; Mumps; MMR vaccine; Rubella; Seroepi­demiologic studies; Seroprevalence; Vaccination; Thailand doi: 10.3329/jhpn.v27i1.3320 J Health Popul Nutr 2009 Feb;27(1): 81-86


    • 1 December 2007
      • Vol. 25  (4) , 219-23

    Seroprevalence of tetanus antibody in the Thai population: a national survey.

    by Pantipa Chatchatee, Susheera Chatproedprai, Porpit Warinsathien, Piyanit Tharmaphornpilas, Pornsak Yoocharoen, Sirisak Warintrawat, Apiradee Theamboonlers, Voranush Chongsrisawat, Yong Poovorawan

    Tetanus is a disease with high mortality and the most important measure for effective prevention is vaccination. Tetanus immunization has been introduced to Thailand's national immunization program for 30 years. Yet, the coverage and seroprevalence of tetanus antibody in vast parts of the population has not been assessed. This study has been performed on 1,277 subjects aged between 6 months and 60 years or above from four geographically distinct provinces of Thailand. Tetanus antibody levels were measured using a commercially available ELISA kit. Most of the Thai population had immunity against tetanus. The level of antibodies to tetanus, as demonstrated by the geometric mean titer of antibody (GMT) (and 95% confidence interval) was 2.62 (2.34-2.91) IU/ml. The highest and lowest GMT was found in subjects aged between 5 and 9 years, and above 60 years of age with GMT (and 95% confidence intervals) of 3.64 (3.34-3.96) and 1.24 (0.67-2.29) IU/ml respectively. The minimum protective level of antitoxin (>0.01 IU/ml) was detected in 99.7 % of subjects. More than 90% of subjects displayed durable antibody protection levels (DAPL) (> or = 1.0 IU/ml), except for subjects above the age of 60 years (82%). According to this study, the majority of the population expresses tetanus antibody levels that can confer long term protection. Yet, considering the lowest GMT and the highest incidence of tetanus cases found in subjects aged above 60 years, re-immunization should be targeted at this age group especially if they had sustained any tetanus-prone injury.


    • 27 November 2007
      • Vol. 25, 175-82

    Seroepidemiology and genotypes of hepatitis C virus in Thailand.

    by Srunthron Sunanchaikarn, Apiradee Theamboonlers, Voranush Chongsrisawat, Pornsak Yoocharoen, Piyanit Tharmaphornpilas, Porpit Warinsathien, Supakarn Sinlaparatsamee, Siriraj Paupunwatana, Kasemporn Chaiear, Sawan Khwanjaipanich, et al.

    HCV can be classified into 6 major genotypes based on the phylogenetic analysis of the genomic sequences. The 3 major genotypes found in Thailand are 3, 1 and 6, respectively. In 2004, an epidemiological survey was carried out to evaluate the seroprevalence of HCV infections among populations aged 2-60 years in four provinces of Thailand, representing the North, Northeast, Center and South of the country, respectively. One hundred and twenty five out of 5,825 serum samples (2.15%) were positive for anti-HCV by ELISA. Fifty eight out of 100 anti-HCV positive samples (58.0%) were positive by RT-PCR of the 5'UTR. The core region of 45 representative samples was sequenced allowing classification into genotype variants 1a (6.7%), 1b (26.7%), 2a (2.2%), 2c (2.2%), 3a (51.1%), 3b (2.2%) and 6 (8.9%). This information might be crucial for public health surveillance and prevention of HCV infection.


  • Open Access

    Diphtheria in Thailand in the 1990s

    by Piyanit Tharmaphornpilas, Pornsak Yoocharoan, Preecha Prempree, Surasak Youngpairoj, Pisit Sriprasert, Charles R. Vitek

    Diphtheria remains endemic in developing countries, but there are limited published data on the subject. Thailand's diphtheria surveillance data are